Defunct Company
Total Trials
11
As Lead Sponsor
10
As Collaborator
1
Total Enrollment
1,506
NCT03595683
Pembrolizumab and EDP1503 in Advanced Melanoma
Phase: Phase 2
Role: Collaborator
Start: Oct 2, 2018
Completion: Nov 2, 2027
NCT03733353
A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 19, 2018
Completion: Oct 29, 2021
NCT03775850
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Start: Dec 19, 2018
Completion: Oct 31, 2021
NCT03542994
A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis
Start: Apr 24, 2019
Completion: Jan 3, 2020
NCT04488575
Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection
Start: Aug 26, 2020
Completion: May 19, 2021
NCT04603027
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
Start: Sep 21, 2020
Completion: Dec 6, 2021
NCT04927195
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
Start: Feb 23, 2021
Completion: Feb 28, 2022
NCT05066373
Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms
Start: Aug 9, 2021
Completion: Aug 26, 2022
NCT05121480
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
Start: Jan 31, 2022
Completion: Mar 28, 2023
NCT05439941
A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials
Start: Jun 6, 2022
Completion: Jun 7, 2023
NCT05682222
Evaluation of the Immunopharmacology of EDP1815 and EDP2939
Start: Jun 27, 2022
Completion: Oct 14, 2022